Magnus Ingelman-Sundberg

Summary

Affiliation: Karolinska Institutet
Country: Sweden

Publications

  1. ncbi Intronic polymorphisms of cytochromes P450
    Magnus Ingelman-Sundberg
    Section of Pharmacogenetics, Department of Physiology and Pharmacology, Karolinska Institutet, SE 17177 Stockholm, Sweden
    Hum Genomics 4:402-5. 2010
  2. ncbi The past, present and future of pharmacoepigenomics
    Magnus Ingelman-Sundberg
    Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden
    Pharmacogenomics 11:625-7. 2010
  3. ncbi Pharmacogenetic biomarkers as tools for improved drug therapy; emphasis on the cytochrome P450 system
    Magnus Ingelman-Sundberg
    Section of Pharmacogenetics, Department of Physiology and Pharmacology, Karolinska Institutet, SE 17177 Stockholm, Sweden
    Biochem Biophys Res Commun 396:90-4. 2010
  4. ncbi Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects
    Magnus Ingelman-Sundberg
    Section of Pharmacogenetics, Department of Physiology and Pharmacology, Karolinska Institutet, SE 17177, Stockholm, Sweden
    Pharmacol Ther 116:496-526. 2007
  5. ncbi Cytochrome P450 1B1 gene polymorphisms and postmenopausal breast cancer risk
    Tove Rylander-Rudqvist
    Division of Molecular Toxicology, Institute of Environmental Medicine, Karolinska Institutet, SE 171 77 Stockholm, Sweden
    Carcinogenesis 24:1533-9. 2003
  6. ncbi Genetic polymorphism of CYP1A2 in Ethiopians affecting induction and expression: characterization of novel haplotypes with single-nucleotide polymorphisms in intron 1
    Eleni Aklillu
    Division of Molecular Toxicology, Institute of Environmental Medicine, Karolinska Institutet, SE 171 77 Stockholm, Sweden
    Mol Pharmacol 64:659-69. 2003
  7. ncbi The transcription factor GATA-4 regulates cytochrome P4502C19 gene expression
    Jessica Mwinyi
    Karolinska Institutet, Department of Physiology and Pharmacology, Section of Pharmacogenetics, 17177 Stockholm, Sweden
    Life Sci 86:699-706. 2010
  8. ncbi Evidence for environmental influence on CYP2D6-catalysed debrisoquine hydroxylation as demonstrated by phenotyping and genotyping of Ethiopians living in Ethiopia or in Sweden
    Eleni Aklillu
    Division of Molecular Toxicology, IMM, Karolinska Institutet, Stockholm, Sweden
    Pharmacogenetics 12:375-83. 2002
  9. ncbi Cytochrome P450 1B1 gene polymorphisms and postmenopausal endometrial cancer risk
    Tove Rylander-Rudqvist
    Division of Molecular Toxicology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden
    Cancer Epidemiol Biomarkers Prev 13:1515-20. 2004
  10. ncbi A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants
    Sarah C Sim
    Division of Molecular Toxicology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm
    Clin Pharmacol Ther 79:103-13. 2006

Detail Information

Publications74

  1. ncbi Intronic polymorphisms of cytochromes P450
    Magnus Ingelman-Sundberg
    Section of Pharmacogenetics, Department of Physiology and Pharmacology, Karolinska Institutet, SE 17177 Stockholm, Sweden
    Hum Genomics 4:402-5. 2010
    ....
  2. ncbi The past, present and future of pharmacoepigenomics
    Magnus Ingelman-Sundberg
    Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden
    Pharmacogenomics 11:625-7. 2010
    ....
  3. ncbi Pharmacogenetic biomarkers as tools for improved drug therapy; emphasis on the cytochrome P450 system
    Magnus Ingelman-Sundberg
    Section of Pharmacogenetics, Department of Physiology and Pharmacology, Karolinska Institutet, SE 17177 Stockholm, Sweden
    Biochem Biophys Res Commun 396:90-4. 2010
    ..In this review we give a background and description of this work as well as the important implications for future medicine...
  4. ncbi Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects
    Magnus Ingelman-Sundberg
    Section of Pharmacogenetics, Department of Physiology and Pharmacology, Karolinska Institutet, SE 17177, Stockholm, Sweden
    Pharmacol Ther 116:496-526. 2007
    ....
  5. ncbi Cytochrome P450 1B1 gene polymorphisms and postmenopausal breast cancer risk
    Tove Rylander-Rudqvist
    Division of Molecular Toxicology, Institute of Environmental Medicine, Karolinska Institutet, SE 171 77 Stockholm, Sweden
    Carcinogenesis 24:1533-9. 2003
    ..In summary, our results strongly indicate that the studied CYP1B1 gene polymorphisms do not influence breast cancer risk overall but may modify the risk after long-term menopausal hormone use...
  6. ncbi Genetic polymorphism of CYP1A2 in Ethiopians affecting induction and expression: characterization of novel haplotypes with single-nucleotide polymorphisms in intron 1
    Eleni Aklillu
    Division of Molecular Toxicology, Institute of Environmental Medicine, Karolinska Institutet, SE 171 77 Stockholm, Sweden
    Mol Pharmacol 64:659-69. 2003
    ....
  7. ncbi The transcription factor GATA-4 regulates cytochrome P4502C19 gene expression
    Jessica Mwinyi
    Karolinska Institutet, Department of Physiology and Pharmacology, Section of Pharmacogenetics, 17177 Stockholm, Sweden
    Life Sci 86:699-706. 2010
    ..In this study we investigated whether the transcription factor family GATA is involved in the regulation of CYP2C19 gene expression...
  8. ncbi Evidence for environmental influence on CYP2D6-catalysed debrisoquine hydroxylation as demonstrated by phenotyping and genotyping of Ethiopians living in Ethiopia or in Sweden
    Eleni Aklillu
    Division of Molecular Toxicology, IMM, Karolinska Institutet, Stockholm, Sweden
    Pharmacogenetics 12:375-83. 2002
    ..Additional factors remain to be elucidated to fully explain the interethnic differences in CYP2D6 activity...
  9. ncbi Cytochrome P450 1B1 gene polymorphisms and postmenopausal endometrial cancer risk
    Tove Rylander-Rudqvist
    Division of Molecular Toxicology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden
    Cancer Epidemiol Biomarkers Prev 13:1515-20. 2004
    ..We found no evidence for an overall association between CYP1B1 genotype and endometrial cancer risk, nor was there any clear indication of gene-environment interaction...
  10. ncbi A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants
    Sarah C Sim
    Division of Molecular Toxicology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm
    Clin Pharmacol Ther 79:103-13. 2006
    ..A significant portion of extensive metabolizers do not reach appropriate drug levels, and our objective was to investigate any genetic background...
  11. ncbi Identification and phenotype characterization of two CYP3A haplotypes causing different enzymatic capacity in fetal livers
    Cristina Rodriguez-Antona
    Division of Molecular Toxicology, Institute of Environmental Medicine, Karolinska Institutet, Nobels vag 13, 171 77 Stockholm, Sweden
    Clin Pharmacol Ther 77:259-70. 2005
    ..CYP3A7 is the most abundant CYP in the human liver during fetal stages and the first months of postnatal age and shows a large interindividual variability of unknown molecular basis...
  12. ncbi Kinetics of omeprazole and escitalopram in relation to the CYP2C19*17 allele in healthy subjects
    Staffan Ohlsson Rosenborg
    Karolinska Institutet, Department of Laboratory Medicine, Division of Clinical Pharmacology, Karolinska University Hospital Huddinge, SE 141 86, Stockholm, Sweden
    Eur J Clin Pharmacol 64:1175-9. 2008
    ..The aim of this study was to compare the impact of the CYP2C19*17 allele on omeprazole single-dose kinetics with escitalopram exposure at steady state in volunteers genotyped as either CYP2C19*17/*17 or CYP2C19*1/*1...
  13. ncbi New insights into the regulation of CYP2C9 gene expression: the role of the transcription factor GATA-4
    Jessica Mwinyi
    Karolinska Institutet, Department of Physiology and Pharmacology, Section of Pharmacogenetics, Stockholm, Sweden
    Drug Metab Dispos 38:415-21. 2010
    ..Taken together, these data strongly suggest an involvement of liver-specific transcription factor GATA-4 in the transcriptional regulation of CYP2C9...
  14. ncbi Functional analysis of six different polymorphic CYP1B1 enzyme variants found in an Ethiopian population
    Eleni Aklillu
    Division of Molecular Toxicology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden
    Mol Pharmacol 61:586-94. 2002
    ..1 enzyme. The results emphasize the necessity of a complete haplotype analysis of enzyme variants for evaluation of functional consequences in vivo and for analyses of genetic polymorphisms in relation to, for example, cancer incidence...
  15. ncbi Colorectal cancer-specific cytochrome P450 2W1: intracellular localization, glycosylation, and catalytic activity
    Alvin Gomez
    Section of Pharmacogenetics, Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden
    Mol Pharmacol 78:1004-11. 2010
    ..Together, these results suggest the possibility of using CYP2W1 as a drug target in the treatment of colon cancer using antibodies and/or specific CYP2W1 activated prodrugs...
  16. ncbi Polymorphic NF-Y dependent regulation of human nicotine C-oxidase (CYP2A6)
    Oliver von Richter
    Institute of Environmental Medicine, Division of Molecular Toxicology, Karolinska Institutet, 17177 Stockholm, Sweden
    Pharmacogenetics 14:369-79. 2004
    ..CONCLUSION: A new haplotype, CYP2A6*1H was identified, with allele frequencies of 3.1% in Swedish and 5.2% in Turkish populations...
  17. ncbi IL-4-mediated transcriptional regulation of human CYP2E1 by two independent signaling pathways
    Jue Wang
    Section of Pharmacogenetics, Department of Physiology and Pharmacology, Karolinska Institute, Nanna Svartz vag 2, 171 77 Stockholm, Sweden
    Biochem Pharmacol 80:1592-600. 2010
    ..In conclusion, the present study indicates that the induction of CYP2E1 transcription by IL-4 is mediated through two independent parallel pathways, involving JAK-STAT6 and IRS1/2 and NFATc1...
  18. ncbi CYP3A4 catalytic activity is induced in confluent Huh7 hepatoma cells
    Louise Sivertsson
    Department of Physiology and Pharmacology, Section of Pharmacogenetics, Karolinska Institutet, Nanna Svartz vag 2, SE 171 77 Stockholm, Sweden
    Drug Metab Dispos 38:995-1002. 2010
    ..Our results show that Huh7 cells grown confluent differentiate into a more metabolically competent cell line, especially with regard to CYP3A4...
  19. ncbi Transcriptional regulation of the human CYP2A6 gene
    Mariá Pitarque
    Institute of Environmental Medicine, Division of Molecular Toxicology, Karolinska Institutet, Stockholm, Sweden
    J Pharmacol Exp Ther 313:814-22. 2005
    ..These results will be important for the identification of new polymorphisms affecting CYP2A6 gene expression...
  20. ncbi Expression of CYP2W1 in colon tumors: regulation by gene methylation
    Alvin Gomez
    Karolinska Institutet, Section of Pharmacogenetics, Department of Physiology and Pharmacology, 171 77 Stockholm, Sweden
    Pharmacogenomics 8:1315-25. 2007
    ..Here, the expression and gene methylation of CYP2W1 were analyzed in human colon carcinoma cell lines, colon tumors and in corresponding normal colon tissue...
  21. ncbi Comparisons of CYP1A2 genetic polymorphisms, enzyme activity and the genotype-phenotype relationship in Swedes and Koreans
    Roza Ghotbi
    Division of Clinical Pharmacology, Karolinska University Hospital Huddinge, Karolinska Institutet, C1 68, 141 86, Stockholm, Sweden
    Eur J Clin Pharmacol 63:537-46. 2007
    ..To investigate the CYP1A2 genotype-phenotype relationship and to compare CYP1A2 genetic polymorphisms and enzyme activity in terms of the effect of smoking and oral contraceptive (OC) use in Swedes and Koreans...
  22. ncbi Characterization of a novel CYP2A7/CYP2A6 hybrid allele (CYP2A6*12) that causes reduced CYP2A6 activity
    Mikael Oscarson
    Division of Molecular Toxicology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden
    Hum Mutat 20:275-83. 2002
    ..The CYP2A6(*)12 allele was present at an allele frequency of 2.2% among Spaniards, but was absent in Chinese...
  23. ncbi The ligands of estrogen receptor α regulate cytochrome P4502C9 (CYP2C9) expression
    Jessica Mwinyi
    Department of Physiology and Pharmacology, Section of Pharmacogenetics, Karolinska Institutet, Stockholm, Sweden
    J Pharmacol Exp Ther 338:302-9. 2011
    ..Taken together, these results indicate that ERα and its ligands play an important role in the regulation of CYP2C9 expression...
  24. ncbi Increased sensitivity for troglitazone-induced cytotoxicity using a human in vitro co-culture model
    Ylva Edling
    Department of Physiology and Pharmacology, Section of Pharmacogenetics, Karolinska Institutet, Nanna Svartz vag 2, 171 77 Stockholm, Sweden
    Toxicol In Vitro 23:1387-95. 2009
    ..Based on these results we suggest that co-cultures of human hepatoma cells and monocytes might provide an important in vitro system for better prediction of cytotoxicity mediated by potential hepatotoxins...
  25. ncbi Xanthine oxidase activity is influenced by environmental factors in Ethiopians
    Eleni Aklillu
    Division of Molecular Toxicology, IMM, Karolinska Institutet, SE 171 77 Stockholm, Sweden
    Eur J Clin Pharmacol 59:533-6. 2003
    ..To investigate xanthine oxidase (XO) polymorphism in Ethiopians and influence of environmental factors, smoking habit and gender-related differences on enzyme activity among Ethiopians living in Ethiopia or Sweden...
  26. ncbi Characterization and tissue distribution of a novel human cytochrome P450-CYP2U1
    Maria Karlgren
    Division of Molecular Toxicology, Institute of Environmental Medicine, Karolinska Institutet, SE 171 77 Stockholm, Sweden
    Biochem Biophys Res Commun 315:679-85. 2004
    ..The physiological and toxicological role of this novel P450 is still unknown, but the selective tissue distribution suggests an important endogenous function...
  27. ncbi CYP3A7 protein expression is high in a fraction of adult human livers and partially associated with the CYP3A7*1C allele
    Sarah C Sim
    Division of Molecular Toxicology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden
    Pharmacogenet Genomics 15:625-31. 2005
    ..The relatively high level of CYP3A7 protein expression detected in a subset of adult livers may be relevant with respect to the metabolism of exogenous and endogenous substrates, such as retinoic acid and dehydroepiandrosterone...
  28. ncbi Comparative analysis of CYP3A expression in human liver suggests only a minor role for CYP3A5 in drug metabolism
    Anna Westlind-Johnsson
    Division of Molecular Toxicology, IMM, Karolinska Institutet, Box 210, SE-171 77 Stockholm, Sweden
    Drug Metab Dispos 31:755-61. 2003
    ....
  29. ncbi Characterization of common CYP1B1 variants with different capacity for benzo[a]pyrene-7,8-dihydrodiol epoxide formation from benzo[a]pyrene
    Eleni Aklillu
    Division of Clinical Pharmacology, Department of Laboratory Medicine, Karolinska University Hospital Huddinge, Stockholm, Sweden
    Cancer Res 65:5105-11. 2005
    ..g., to lung cancer induced by smoking). The results indicate the necessity to make molecular epidemiologic investigations regarding the association of the specific CYP1B1 haplotypes and cancer risk...
  30. ncbi New approaches and applications in chemical biology
    Alvin Gomez
    Division of Molecular Toxicology, IMM, Karolinska Institutet, SE-171 77 Stockholm, Sweden
    Drug News Perspect 17:594-605. 2004
    ..At the meeting, 73 different lectures were presented and about 240 posters were shown. This review discusses most of the lectures presented at the Symposium...
  31. ncbi Catechol-O-methyltransferase gene polymorphism and post-menopausal breast cancer risk
    Sara Wedren
    Department of Medical Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, SE 171 77 Stockholm, Sweden
    Carcinogenesis 24:681-7. 2003
    ..Based on our findings, COMT activity alone does not seem to play a major role in breast carcinogenesis, but may be of importance in certain histotypes or in conjunction with other exposures...
  32. ncbi Regulation of CYP2C19 expression by estrogen receptor α: implications for estrogen-dependent inhibition of drug metabolism
    Jessica Mwinyi
    Section of Pharmacogenetics, Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden
    Mol Pharmacol 78:886-94. 2010
    ....
  33. ncbi 3'-UTR polymorphism in the human CYP2A6 gene affects mRNA stability and enzyme expression
    Jue Wang
    Division of Molecular Toxicology, Institute of Environmental Medicine, Karolinska Institute, Stockholm, Sweden
    Biochem Biophys Res Commun 340:491-7. 2006
    ..Such polymorphism has been described to influence the in vivo rate of nicotine elimination and possibly the cigarette consumption and risk of smoking induced lung cancer...
  34. ncbi Amidoxime reductase system containing cytochrome b5 type B (CYB5B) and MOSC2 is of importance for lipid synthesis in adipocyte mitochondria
    Etienne P A Neve
    Section of Pharmacogenetics, Department of Physiology and Pharmacology, Karolinska Institutet, SE 17177 Stockholm
    J Biol Chem 287:6307-17. 2012
    ....
  35. ncbi Allele-specific expression and gene methylation in the control of CYP1A2 mRNA level in human livers
    Roza Ghotbi
    Division of Clinical Pharmacology, Department of Laboratory Medicine, Karolinska University Hospital Huddinge, Karolinska Institutet, Stockholm, Sweden
    Pharmacogenomics J 9:208-17. 2009
    ..In conclusion, the CYP1A2 gene expression is influenced by the extent of DNA methylation and displays ASE, mechanisms contributing to the large interindividual differences in CYP1A2 gene expression...
  36. ncbi Identification of sequences responsible for intracellular targeting and membrane binding of rat CYP2E1 in yeast
    Etienne P A Neve
    Division of Molecular Toxicology, Institute of Environmental Medicine, Karolinska Institutet, SE 171 77 Stockholm, Sweden
    Biochemistry 42:14566-75. 2003
    ..We suggest that these amino acid changes at positions 90 and 91 abolish the electrostatic interaction between the negatively charged membrane and the positively charged B-helix, thereby producing a soluble product...
  37. ncbi Association between CYP2C19 polymorphism and depressive symptoms
    Sarah C Sim
    Section of Pharmacogenetics, Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden
    Am J Med Genet B Neuropsychiatr Genet 153:1160-6. 2010
    ..0001). Our results suggest for the first time that the CYP2C19 polymorphism might be of importance for depressive symptoms, as here shown for older European adults...
  38. ncbi The impact of CYP2E1 on the development of alcoholic liver disease as studied in a transgenic mouse model
    Angelica Butura
    Section of Pharmacogenetics, Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden
    J Hepatol 50:572-83. 2009
    ..The present study aims to evaluate the role of CYP2E1 in combination with ethanol for development of alcoholic liver disease using mice transgenic for the human CYP2E1 gene...
  39. ncbi Phenotype-genotype variability in the human CYP3A locus as assessed by the probe drug quinine and analyses of variant CYP3A4 alleles
    Cristina Rodriguez-Antona
    Division of Molecular Toxicology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden
    Biochem Biophys Res Commun 338:299-305. 2005
    ..The data indicate the existence of a genetic CYP3A4 polymorphism with functional importance for interindividual differences in enzyme expression...
  40. ncbi DNA methylation dynamics in the hepatic CYP3A4 gene promoter
    Marina Kacevska
    Section of Pharmacogenetics, Department of Physiology and Pharmacology, Karolinska Institutet, SE 171 77 Stockholm, Sweden
    Biochimie 94:2338-44. 2012
    ..The findings provide novel insight to CYP3A4 regulation with possible implications for understanding interindividual differences in drug response...
  41. ncbi The Human Cytochrome P450 (CYP) Allele Nomenclature website: a peer-reviewed database of CYP variants and their associated effects
    Sarah C Sim
    Section of Pharmacogenetics, Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden
    Hum Genomics 4:278-81. 2010
    ..Thus, the CYP-allele website offers a rapid online publication of new alleles, as well as providing an overview of peer-reviewed data...
  42. ncbi Epigenetic and microRNA-dependent control of cytochrome P450 expression: a gap between DNA and protein
    Alvin Gomez
    Section of Pharmacogenetics, Department of Physiology and Pharmacology, Karolinska Institutet, Sweden
    Pharmacogenomics 10:1067-76. 2009
    ..In this review we discuss known epigenetic and microRNA-dependent regulation of the human drug-metabolizing cytochromes P450 to help explain the unknown factors of variable drug response...
  43. ncbi Pharmacogenetics of drug-metabolizing enzymes: implications for a safer and more effective drug therapy
    Magnus Ingelman-Sundberg
    Division of Molecular Toxicology, IMM, Karolinska Institutet, Nobels vag 13, 171 77 Stockholm, Sweden
    Philos Trans R Soc Lond B Biol Sci 360:1563-70. 2005
    ..However, it will take time before this will be a reality within the clinic. We describe some important aspects in the field with emphasis on cytochrome P450 and discuss also polymorphic aspects of foetal expression of CYP3A5 and CYP3A7...
  44. ncbi Increased omeprazole metabolism in carriers of the CYP2C19*17 allele; a pharmacokinetic study in healthy volunteers
    R Michael Baldwin
    Section of Pharmacogenetics, Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden
    Br J Clin Pharmacol 65:767-74. 2008
    ..The CYP2C19*17 allele had been associated with a two- and fourfold decrease in omeprazole and S/R-mephenytoin metabolic ratios...
  45. ncbi Current research in drug metabolism, drug transport and drug development
    Inger Johansson
    Section of Pharmacogenetics, Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden
    Drug News Perspect 21:518-28. 2008
    ..The meeting consisted of 8 plenary sessions, 12 symposia with a total of 60 lectures and 185 abstracts. This report provides a summary of the meeting...
  46. ncbi Human drug metabolising cytochrome P450 enzymes: properties and polymorphisms
    Magnus Ingelman-Sundberg
    Division of Molecular Toxicology, Institute of Environmental Medicine, Karolinska Institutet, Nobels vag 13, 171 77, Stockholm, Sweden
    Naunyn Schmiedebergs Arch Pharmacol 369:89-104. 2004
    ..In this contribution an update of human cytochrome P450 enzymology and pharmacogenetics is given with particular emphasis on CYP1B1, CYP2B6, CYP2E1 and CYP3As...
  47. ncbi Tumour-specific expression of CYP2W1: its potential as a drug target in cancer therapy
    Maria Karlgren
    Karolinska Institutet, Section of Pharmacogenetics, Department of Physiology and Pharmacology, SE 171 77 Stockholm, Sweden
    Expert Opin Ther Targets 11:61-7. 2007
    ..Here, the authors review the data currently available for this enzyme and discuss its potential as a drug target...
  48. ncbi Activation of c-fos by lipopolysaccharide in glial cells via p38 mitogen-activated protein kinase-dependent activation of serum or cyclic AMP/calcium response element
    Anastasia Simi
    Institute of Environmental Medicine, Division of Molecular Toxicology, Karolinska Institute, Stockholm, Sweden
    J Neurochem 92:915-24. 2005
    ..Elk1-mediated transactivation was dependent on p38 MAPK, suggesting a crucial role of these factors in mediating inflammatory responses in the CNS...
  49. ncbi A nicotine C-oxidase gene (CYP2A6) polymorphism important for promoter activity
    Mariá Pitarque
    Institute of Environmental Medicine, Division of Molecular Toxicology, Karolinska Institutet, Stockholm, Sweden
    Hum Mutat 23:258-66. 2004
    ..In conclusion, our results indicate the presence of a strong enhancer or promoter responsive element between c.-1005 and c.-1019 in the CYP2A6 gene and that a c.-1013A>G polymorphism in this region affects CYP2A6 transcription...
  50. ncbi Different structural requirements of the ligand binding domain of the aryl hydrocarbon receptor for high- and low-affinity ligand binding and receptor activation
    Maria Backlund
    Division of Molecular Toxicology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden
    Mol Pharmacol 65:416-25. 2004
    ..In addition, the data presented here indicate that Tyr320 plays an important role in AhR activation...
  51. ncbi Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future
    Magnus Ingelman-Sundberg
    Division of Molecular Toxicology, IMM, Karolinska Institutet, SE 171 77 Stockholm, Sweden
    Trends Pharmacol Sci 25:193-200. 2004
    ..I estimate that such personalized P450 gene-based treatment would be relevant for 10-20% of all drug therapy...
  52. ncbi Identification and characterization of CYP3A4*20, a novel rare CYP3A4 allele without functional activity
    Anna Westlind-Johnsson
    Division of Molecular Toxicology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden
    Clin Pharmacol Ther 79:339-49. 2006
    ..We aimed to investigate the genetic background of this finding...
  53. ncbi The expression of CYP2W1: a prognostic marker in colon cancer
    Kristina Stenstedt
    Department of 1Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden
    Anticancer Res 32:3869-74. 2012
    ..The aim of this study was to validate the pilot study's results using a larger, independent group of patients with colon cancer...
  54. ncbi Influence of sex on propofol metabolism, a pilot study: implications for propofol anesthesia
    Irena Loryan
    Section of Pharmacogenetics, Department of Physiology and Pharmacology, Karolinska Institutet, SE 171 77, Stockholm, Sweden
    Eur J Clin Pharmacol 68:397-406. 2012
    ....
  55. ncbi Characterization and partial purification of the rat and human enzyme systems active in the reduction of N-hydroxymelagatran and benzamidoxime
    Susanne Andersson
    Division of Molecular Toxicology, IMM, Karolinska Institutet, SE-171 77 Stockholm, Sweden
    Drug Metab Dispos 33:570-8. 2005
    ....
  56. ncbi Regulation of aryl hydrocarbon receptor signal transduction by protein tyrosine kinases
    Maria Backlund
    Division of Molecular Toxicology, Institute of Environmental Medicine, Karolinska Institutet, SE 171 77, Stockholm, Sweden
    Cell Signal 17:39-48. 2005
    ....
  57. ncbi Differentiation of human hepatoma cells during confluence as revealed by gene expression profiling
    Angelica Butura
    Division of Molecular Toxicology, Institute of Environmental Medicine, Karolinska Institutet, SE-171 77 Stockholm, Sweden
    Biochem Pharmacol 67:1249-58. 2004
    ....
  58. ncbi Intracellular transport and localization of microsomal cytochrome P450
    Etienne P A Neve
    Section of Pharmacogenetics, Department of Physiology and Pharmacology, Karolinska Institutet, Nanna Svartz vag 2, 171 77, Stockholm, Sweden
    Anal Bioanal Chem 392:1075-84. 2008
    ..In this review we present an update of the field emphasizing studies concerning localization, posttranslational modification, such as phosphorylation, and intracellular transport of microsomal P450s...
  59. ncbi Cytochrome P450 proteins: retention and distribution from the endoplasmic reticulum
    Etienne P A Neve
    Karolinska Institutet, Section of Pharmacogenetics, Department of Physiology and Pharmacology, Nanna Svartz vag 2, 171 77 Stockholm, Sweden
    Curr Opin Drug Discov Devel 13:78-85. 2010
    ..This review discusses the mechanisms of intracellular CYP transport, and the implications of the presence of CYP proteins in extra-ER compartments for drug metabolism and toxicity...
  60. ncbi Hepatic expression of multiple acute phase proteins and down-regulation of nuclear receptors after acute endotoxin exposure
    Che Fang
    Division of Molecular Toxicology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm 17177, Sweden
    Biochem Pharmacol 67:1389-97. 2004
    ..These data suggest that acute LPS treatment induces important early transcription factors and co-ordinately down-regulates nuclear receptors, and that this results in altered expression of a large number of downstream genes...
  61. ncbi Glutamate activates c-fos in glial cells via a novel mechanism involving the glutamate receptor subtype mGlu5 and the transcriptional repressor DREAM
    Ylva Edling
    Department of Physiology and Pharmacology, Karolinska Institutet, SE 171 77 Stockholm, Sweden
    Glia 55:328-40. 2007
    ..These findings are in sharp contrast to the mechanism described in neurons and suggest a novel pathway activated by glutamate in glial cells that employs mGluR5, ER calcium, and the derepression of c-fos at the DRE...
  62. ncbi Polymorphism of cytochrome P450 and xenobiotic toxicity
    Magnus Ingelman-Sundberg
    Division of Molecular Toxicology, Institute of Environmental Medicine, IMM, Karolinska Institute, Box 210, SE 171 77 Stockholm, Sweden
    Toxicology 181:447-52. 2002
    ..In the present overview recent aspects of cytochrome P450 polymorphism and xenobiotic toxicity are discussed...
  63. ncbi The human genome project and novel aspects of cytochrome P450 research
    Magnus Ingelman-Sundberg
    Division of Molecular Toxicology, IMM, Karolinska Institutet, SE 171 77 Stockholm, Sweden
    Toxicol Appl Pharmacol 207:52-6. 2005
    ..Here, a short review of the current knowledge is given...
  64. ncbi In-solution hybrid capture of bisulfite-converted DNA for targeted bisulfite sequencing of 174 ADME genes
    Maxim Ivanov
    Section of Pharmacogenetics, Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm 17177, Sweden, Estonian Genome Center, University of Tartu, Tartu 51010, Estonia, Estonian Biocentre, Tartu 51010, Estonia and Department of Biotechnology, Institute of Molecular and Cell Biology, University of Tartu, Tartu 51010, Estonia
    Nucleic Acids Res 41:e72. 2013
    ....
  65. ncbi Institutional profile: Karolinska Institutet
    Erik Eliasson
    Karolinska Institutet, Department of Laboratory Medicine, Clinical Pharmacology, Karolinska University Hospital Huddinge, Stockholm, Sweden
    Pharmacogenomics 13:1887-91. 2012
    ..Furthermore, the recently opened Center for Hematology and Regenerative Medicine, with a clear translational emphasis, offers an opportunity for studying drug metabolism and toxicity in vitro by use of human hepatocytes...
  66. ncbi Novel extrahepatic cytochrome P450s
    Maria Karlgren
    Division of Molecular Toxicology, Institute of Environmental Medicine, Karolinska Institutet, SE 171 77 Stockholm, Sweden
    Toxicol Appl Pharmacol 207:57-61. 2005
    ....
  67. ncbi Pro-inflammatory response and adverse drug reactions: mechanisms of action of ximelagatran on chemokine and cytokine activation in a monocyte in vitro model
    Ylva Edling
    Department of Physiology and Pharmacology, Section of Pharmacogenetics, Karolinska Institutet, Nanna Svartz vag 2, Stockholm, Sweden
    Toxicol In Vitro 22:1588-94. 2008
    ..It is concluded that human monocytes might constitute a valuable additional in vitro model for monitoring the basis for cytotoxic action of drugs...
  68. ncbi Databases in the area of pharmacogenetics
    Sarah C Sim
    Section of Pharmacogenetics, Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden
    Hum Mutat 32:526-31. 2011
    ..Here, we review the databases that provide useful information in this respect, of benefit for the development of the pharmacogenomic field...
  69. ncbi Genetic polymorphism and toxicology--with emphasis on cytochrome p450
    Inger Johansson
    Section of Pharmacogenetics, Department of Physiology and Pharmacology, Karolinska Institutet, 171 77 Stockholm, Sweden
    Toxicol Sci 120:1-13. 2011
    ..In this review, we provide an update of the field with emphasis on CYP polymorphism...
  70. ncbi The human cytochrome P450 Allele Nomenclature Committee Web site: submission criteria, procedures, and objectives
    Sarah C Sim
    Division of Molecular Toxicology, IMM, Karolinska Institutet, Stockholm, Sweden
    Methods Mol Biol 320:183-91. 2006
    ..The CYP allele Web site offers a rapid on-line publication of new alleles, provides an overview of peer-reviewed data, and serves as a form of quality control on research on new alleles...
  71. ncbi Expression of drug metabolizing enzymes in hepatocyte-like cells derived from human embryonic stem cells
    Monica Ek
    Section of Pharmacogenetics, Department of Physiology and Pharmacology, Karolinska Institutet, SE 17177 Stockholm, Sweden
    Biochem Pharmacol 74:496-503. 2007
    ....
  72. ncbi Dietary long-chain n-3 fatty acids for the prevention of cancer: a review of potential mechanisms
    Susanna C Larsson
    Division of Nutritional Epidemiology, The National Institute of Environmental Medicine, Karolinska Institutet, Stockholm
    Am J Clin Nutr 79:935-45. 2004
    ..Further studies are needed to evaluate and verify these mechanisms in humans to gain more understanding of the effects of n-3 fatty acid intake on cancer risk...
  73. ncbi Human CYP allele database: submission criteria procedures and objectives
    Magnus Ingelman-Sundberg
    Division of Molecular Toxicology, IMM, Karolinska Institutet, SE-171 77 Stockholm, Sweden
    Methods Enzymol 357:28-36. 2002
  74. ncbi CYP17 gene polymorphism in relation to breast cancer risk: a case-control study
    Kristjana Einarsdóttir
    Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden
    Breast Cancer Res 7:R890-6. 2005
    ..The c.1-34T>C 5' promoter region polymorphism in cytochrome P450c17 (CYP17), a key enzyme in the biosynthesis of estrogen, has been associated with breast cancer risk, but most previous studies have been relatively small...